Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of HDM2017 for injection, according to a Shenzhen bourse filing on Thursday.
The drug is used in combination with Fruquintinib for the treatment of advanced colorectal cancer.